Migraine Drugs Companies, Investment and Capital Allocation

Who are the Migraine Drugs Market Top Vendors and What are Their Offerings?

Companies and Their Offerings

AbbVie

Headquarters: North Chicago, U.S.
Migraine Drugs: Ubrelvy and Qulipta

Pfizer

Headquarters: New York, U.S.
Migraine Drugs: Nurtec ODT and Zavzpret

Eli Lilly and Company

Headquarters: Indianapolis, U.S.
Migraine Drugs: Reyvow and Emgality

Amgen

Headquarters: Thousand Oaks, U.S.
Migraine Drugs: Aimovig

Teva Pharma

Headquarters: Tel Aviv, Israel
Migraine Drugs: Ajovy

Lundbeck

Headquarters: Valby, Denmark
Migraine Drugs: Vyepti

Axsome

Headquarters: New York, U.S.
Migraine Drugs: Symbravo

Novartis

Headquarters: Basel, Switzerland
Migraine Drugs: Aimovig

GSK

Headquarters: London, UK
Migraine Drugs: Imigran or Imitrex

Biohaven

Headquarters: New Haven, U.S.
Migraine Drugs: Nurtec ODT

Migraine Drugs Market Value Chain Analysis

R&D

• The R&D of the migraine drugs focuses on developing products targeting PACAP neuropeptide and TRP ion channels.
• Key players: Pfizer, Biohaven, Eli Lilly and Company.

Clinical Trials and Regulatory Approvals

• The long-term tolerability, efficacy, and safety profile are evaluated in the clinical trials and regulatory approval of the migraine drugs.
• Key players: Pfizer, Eli Lilly and Company, AbbVie.

Patient Support and Services

• The patient support and services of migraine drugs include personalized nursing support, financial aid, and co-pay cards to improve access to the drugs.
• Key players: Pfizer, Eli Lilly and Company, AbbVie.

Market Growth

The global migraine drugs market size was estimated at USD 7.6 billion in 2025 and is predicted to increase from USD 8.43 billion in 2026 to approximately USD 21.46 billion by 2035, expanding at a CAGR of 10.94% from 2026 to 2035

What are the Recent Developments in the Migraine Drugs Market?

• In January 2026, pivotal Phase 3 data of AJOVY, a product developed for the treatment of episodic migraine in pediatric patients, was released in the New England Journal of Medicine (NEJM), where its efficacy and safety data were highlighted, as per the recent announcement of Teva Pharmaceuticals.
• In November 2025, Rimegepant ODT, a 75 mg oral tablet, was launched by Pfizer as a new treatment for migraine in India. The medication can be administered without water, where it offers at least 48 hours of rapid pain relief.

Partner with our experts to explore the Migraine Drugs Market at sales@towardshealthcare.com